Skip to content

Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training

Effect of Off-site Assistance on Success Rate of Selective Cannulation During Hands-on ERCP Training: A Randomized Non-inferiority Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05249400
Enrollment
600
Registered
2022-02-21
Start date
2020-11-30
Completion date
2023-12-31
Last updated
2023-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Diseases, ERCP Training, Pancreatic Diseases

Brief summary

Endoscopic retrograde cholangiopancreatography (ERCP) is a technically challenging procedure. It takes time to learn the basic skills and need at least 180 - 200 cases for trainees to achieve competency in ERCP. Hands-on practice in patients remains the gold standard for ERCP training. Traditional hands-on ERCP training requires the trainer to be on-site to assist the trainee with ERCP operations. We hypothesized that the trainee can be safely guided by trainer off-site with interactive audio and endoscopic and fluoroscopic view. Technology-enabled health care at a distance has profound scientific potential and accordingly has been met with growing interest. Teleguidance facilitated ERCP cannulation is a strategy to provide expert cannulation guidance to trainee in settings where such expertise is not on-site. Teleguidance not only reduces unnecessary radiation exposure of endoscopist, but also provides remote assistance for trainees to complete training or further improve skills. Given the advantages of the off-site teleguidance, it could be an attractive substitute for on-site hands-on ERCP training. The primary aim of this study was to evaluate whether off-site assistance (Off group) could achieve a comparable success rate to on-site assistance (On group) regarding the rates of successful selective biliary cannulation during ERCP training.

Interventions

PROCEDUREOff-site assistance

The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.

Sponsors

Air Force Military Medical University, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-90 years old * With native papilla

Exclusion criteria

* History of partial or total gastrectomy (Billroth I/II, Roux-en-Y) * Type II duodenal stenosis * Previously failed cannulation * Chronic pancreatitis with stones in the pancreatic head * Hemodynamic instability * Lactating or pregnant women * Inability to give written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Success rate of selective cannulation by traineeup to one yearThe rate of successful selective cannulation by trainee during the training period.

Secondary

MeasureTime frameDescription
Complication rateup to one yearPost-ERCP pancreatitis (mild, moderate-to-severe); Hyperamylasemia; Cholangitis (mild, moderate, severe); Perforation (conservative therapy, surgery); Bleeding (mild, moderate, severe);
Performance score of selective cannulationup to one yearThe trainee's performance score of cannulation by trainer and performance video. Out of 5 points, higher scores are better
Final success rate of cannulationup to one yearThe overall rate of successful selective cannulation by trainee and trainer
Total time of successful cannulationup to one yearTotal time required for successful cannulation
Radiation exposure timeup to one yearRadiation exposure time for trainee and trainer

Countries

China

Contacts

Primary ContactYanglin Pan, M.D.
yanglinpan@gmail.com86-20-84771536
Backup ContactHui Luo, M.D.
fmmulh@163.com86-20-84771536

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026